147219-20-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(E)-3-(3,4-dimethylphenyl)acrylic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the structures of various medicinal compounds. Its unique chemical properties allow it to be a valuable building block in the development of new drugs.
Used in Agrochemical Production:
In the agrochemical industry, (E)-3-(3,4-dimethylphenyl)acrylic acid is used as a starting material for the production of various agrochemicals. Its chemical versatility makes it suitable for the creation of compounds that can be used in the agricultural sector to improve crop yields and protect plants from pests and diseases.
Used in Organic Compounds Synthesis:
(E)-3-(3,4-dimethylphenyl)acrylic acid is utilized as a key intermediate in the synthesis of other organic compounds, showcasing its importance in organic chemistry. Its trans double bond and unique structure enable it to participate in various chemical reactions, leading to the formation of a wide range of products.
Used in Research and Development:
(E)-3-(3,4-dimethylphenyl)acrylic acid is also used in the field of research and development, particularly in organic chemistry. Its potential antioxidant and antimicrobial properties make it an interesting subject for scientific investigation, with the aim of discovering new applications and enhancing its utility in various industries.
Used in Antioxidant Applications:
Due to its potential antioxidant properties, (E)-3-(3,4-dimethylphenyl)acrylic acid can be used as an additive in the food and cosmetic industries to extend the shelf life of products and protect them from oxidative damage.
Used in Antimicrobial Applications:
The antimicrobial properties of (E)-3-(3,4-dimethylphenyl)acrylic acid make it a candidate for use in the development of new antimicrobial agents, which could be applied in the medical, food preservation, and water treatment industries to combat the growth of harmful microorganisms.

Upstream product

• 141-82-2 malonic acid 
• 22884-95-3 3,4-dimethylbenzonitrile 
• 6966-10-5 3,4-dimethylbenzyl alcohol 
• 619-04-5 3,4-dimethylbenzoic acid 
• 5973-71-7 3,4-dimethylbenzaldehyde 
• 95-47-6 o-xylene 
• 79-10-7 acrylic acid 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 21900-23-2 3,4-dimethylbenzoyl chloride 
• 1018448-69-5 (E)-methyl 3-(3,4-dimethylphenyl)acrylate 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 38404-42-1 methyl 3,4-dimethylbenzoate 

Downstream Products

• 25173-76-6 3-(3,4-dimethylphenyl)propionic acid 
• 1246218-88-1 1,8-bis(4'-(3,4-dimethylcinnamamido)phenyl)naphthalene 

Relevant academic research and scientific papers

Photoinduced Regioselective Olefination of Arenes at Proximal and Distal Sites

The Fujiwara-Moritani reaction has had a profound contribution in the emergence of contemporary C-H activation protocols. Despite the applicability of the traditional approach in different fields, the associated reactivity and regioselectivity issues had

Visible-light promoted oxidative cyclization of cinnamic acid derivatives using xanthone as the photocatalyst

We have developed an efficient photocatalytic synthesis of coumarin derivativesviaa tandem double bond isomerization/oxidative cyclization of cinnamic acids. Inexpensive and stable xanthone was used as the photocatalyst, and readily available Selectfluor was used as the oxidant. This method tolerates a wide range of functional groups and offers excellent chemical yields in general. Besides, the photocatalytic oxidative cyclization of cinnamic acid esters gives dimerized lignan-type products.

Kukoamine B derivative compound, preparation method and applications thereof

The invention relates to a kukoamine B derivative compound, a preparation method and applications thereof, and belongs to the field of biological medicines, wherein the structural general formula is represented by a formula (I) or a formula (II), R1, R2, R3 and R4 are respectively and independently any one selected from -OH, -OCH3, -CH3 and -NH2, R5, R6 and R7 are respectively and independently any one selected from H, -CH3, -CH2NH2, -CH2CH2NH2 and -CH2CH2CH2NH2, and m is a natural number. According to the invention, a series of kukoamine B derivative compounds are synthesized and prepared, and are used as PD-1/PD-L1 axis inhibitors for the first time, and anti-tumor effect is realized by inhibiting PD-1/PD-L1 binding so as to provide new drug selection for the prevention and/or treatmentof tumors.

Substituted cinnamic anhydrides act as selective inhibitors of acetylcholinesterase

Cinnamic anhydrides have been shown to be more than reactive reagents, but they also act as inhibitors of the enzyme acetylcholinesterease (AChE). Thus, out of a set of 33 synthesised derivatives, several of them were mixed type inhibitors for AChE (from electric eel). Thus, (E)-3-(2,4-dimethoxyphenyl)acrylic anhydride (2c) showed Ki = 8.30 ± 0.94 μM and Ki′ = 9.54 ± 0.38 μM, and for (E)-3-(3-chlorophenyl)acrylic anhydride (2u) Ki = 8.23 ± 0.93 μM and Ki′ = 13.07 ± 0.46 μM were measured. While being not cytotoxic to many human cell lines, these compounds showed an unprecedented and noteworthy inhibitory effect for AChE but not for butyrylcholinesterase (BChE).

Synthesis and Hypoglycemic Activity of Aryl(Hetaryl)Propenoic Cyanopyrrolidine Amides

Abstract: A series of amides based on (2S)-cyanopyrrolidine and α, β-unsaturated aryl- and hetarylcarboxylic acids have been synthesized. The dependence of the hypoglycemic activity of compounds on the structure of the aromatic fragment has been studied in the oral glucose tolerance test in mice. Amides based on (E)-3-phenylprop-2-enoic and (E)-3-(4-methoxyphenyl)prop-2-enoic acids and (2S)-cyanopyrrolidine have been shown to significantly reduce blood glucose levels in mice. The observed hypoglycemic effect at a dose of 10 mg/kg is comparable to the effect of hypoglycemic drug vildagliptin.

Ligand-accelerated non-directed C-H functionalization of arenes

The directed activation of carbon-hydrogen bonds (C-H) is important in the development of synthetically useful reactions, owing to the proximity-induced reactivity and selectivity that is enabled by coordinating functional groups. Palladium-catalysed non-directed C-H activation could potentially enable further useful reactions, because it can reach more distant sites and be applied to substrates that do not contain appropriate directing groups; however, its development has faced substantial challenges associated with the lack of sufficiently active palladium catalysts. Currently used palladium catalysts are reactive only with electron-rich arenes, unless an excess of arene is used, which limits synthetic applications. Here we report a 2-pyridone ligand that binds to palladium and accelerates non-directed C-H functionalization with arene as the limiting reagent. This protocol is compatible with a broad range of aromatic substrates and we demonstrate direct functionalization of advanced synthetic intermediates, drug molecules and natural products that cannot be used in excessive quantities. We also developed C-H olefination and carboxylation protocols, demonstrating the applicability of our methodology to other transformations. The site selectivity in these transformations is governed by a combination of steric and electronic effects, with the pyridone ligand enhancing the influence of sterics on the selectivity, thus providing complementary selectivity to directed C-H functionalization.

Design, synthesis and cytotoxic evaluation of novel imatinib amide derivatives that target Abl kinase

Novel imatinib amide derivatives (a1-28, b1-9) were synthesized and evaluated for their biological activities. All compounds were characterized by 1H NMR, MS and elemental analysis. Among all the derivatives, compounds a4, a10, a21, b1 and b2 displayed the most significant ability of inhibiting K562 cell proliferation with the IC50 values of 0.67, 0.66, 0.65, 0.59 and 0.62 μM, respectively, indicating that these compounds were potent inhibitors of Bcr-Abl in leukemic K562 cells, comparable to the reference compound imatinib. Molecular docking study was performed to position compounds a21 and b1 into the active site of Abl to determine the probable binding modes

1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives of formula (II), wherein the chirality is as depicted below, (II) and their use as orexin receptor antagonists.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

LIGANDS AND CATALYSTS FOR PRODUCING ELASTOMERIC PROPYLENE POLYMERS

A ligand useful to form a metallocene olefin polymerization catalyst comprises:wherein at least R3 and R4 are substituents having at least a bulk of a t-butyl group and, optionally, wherein R1 or R2 may be a bulky substituent group.